Figure 2: Addition of IL-33 treatment to OVA asthma model mice. | Nature Communications

Figure 2: Addition of IL-33 treatment to OVA asthma model mice.

From: Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation

Figure 2

(a) OVA+IL-33-induced asthma model mice were treated by administration for 3 consecutive days of OVA (10 ng) and IL-33 (0.1 μg). The mice had been sensitized with OVA and alum. Dexamethasone (5 mg kg−1) was intraperitoneally injected at 24 and 1 h before OVA/IL-33 administration for some mice. (b,c) Number of eosinophils in the BALF (b) and NH cells in the lungs (c) 4 days after the final administration of OVA/IL-33 or vehicle (PBS). Mean±s.e.m., n=3–4 for each group. NS, not significant. *P<0.05, **P<0.01 (Student’s t-test). (d) Amounts of IL-5 (d) and IL-13 (e) in the BALF. Mean±s.e.m., n=3–4 for each group. NS, not significant. *P<0.05 (Student’s t-test). (f) Histology of the airways from these mice stained with hematoxylin and eosin (left panels) or periodic acid–Schiff (PAS)-alcian blue (right panels). Scale bar, 100 μm. (g) Intracellular staining of IL-5 and IL-13 in CD4+ T cells and NH cells. Data are representatives of three independent experiments.

Back to article page